NTRK2 and Parkinson disease: Additionally, it is worth noting that attempting to rescue degenerating midbrain dopamine neurons via intracranial administration of neurotrophic factors may not exert a therapeutic benefit given that BDNF receptors (TrkB) at the cell membrane are eventually lost in degenerating neurons as the disease progresses in PD patients, thereby impeding its mechanism of action.